Logo of Xenitra (ASX:XEN)Latest Xenitra (ASX:XEN) News

Page 1
Page 1 of 2

Xenitra targets A$100 million in sales through JD Health partnership

Xenitra has secured a three-year strategic cooperation agreement with JD Health carrying a non-binding A$100 million sales target across prescription medicines, OTC products, FSMP products and health products. The first order is expected in December, with sales targeted to begin in January 2027, but the agreement does not guarantee revenue or impose a penalty if the target is missed.
Victor Sage
18 Nov 2026

Xenitra Returns to Positive Gross Profit as Pharmaceuticals and Web3 Commerce Scale

Xenitra has returned to positive quarterly gross profit as its new pharmaceutical and Web3 businesses begin generating revenue, but statutory operating cash flow remained negative at A$790,000. The company is now relying on procurement targets, repeat Web3 sales and further capital discipline to turn early commercial activity into sustainable cash generation.
Victor Sage
30 Oct 2026

Xenitra Raises A$1.5 Million to Boost Higher-Margin Sales Across OTC and Tokenised Channels

Xenitra Limited has secured A$1.5 million through a discounted share placement to accelerate growth in higher-margin OTC medicines, FSMP, and tokenised FMCG sales. The capital will fund inventory expansion, supplier fulfilment, and ecommerce activation as the company shifts from low-margin distribution to a diversified healthcare platform.
Victor Sage
24 Aug 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

Xenitra Expands Healthcare Reach with A$5 Million FSMP Procurement Deal

Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.
Ada Torres
18 Aug 2026

Market Wrap - Week 31 (27 July -> 31 July) 2026

Small-cap shares produced the week’s biggest moves, led by Xenitra’s 60% surge and Carnaby Resources’ takeover jump.
Mining news dominated, but sharp falls in Lotus Resources and several funded developers showed that new capital can still unsettle investors.
Logan Eniac
1 Aug 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Xenitra Posts A$0.8 Million Operating Cash Flow as OTC and OPAL Sales Gain Traction

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.
Victor Sage
30 July 2026

Xenitra Locks In A$12 Million OTC Pharmaceutical Deal With Kangsheng

Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.
Ada Torres
27 July 2026

Xenitra’s OPAL Tokenised Sales Surpass $1.1 Million with 400+ Partners in Seven Weeks

Xenitra Limited’s OPAL Real World Asset tokenised sales ecosystem has accelerated rapidly, crossing $1.1 million in product sales and onboarding over 400 distribution partners within seven weeks, signalling strong traction in Greater China.
Victor Sage
4 June 2026

Xenitra Secures Exclusive $5M Biomiq Skincare Deal in Greater China

Xenitra Limited has locked in a four-year exclusive distribution agreement for Biomiq Skincare in Greater China, targeting $5 million in minimum purchases and integrating the brand into its blockchain tokenised sales ecosystem.
Victor Sage
2 June 2026

Xenitra's OPAL Tokenised Sales Surpass $500k in First Month with 130+ Distributors

Xenitra Limited's OPAL Real World Asset tokenised sales ecosystem has generated over $500,000 in sales within its first month, onboarding more than 130 distributors and positioning the company as an early mover in blockchain-enabled FMCG sales in China.
Victor Sage
14 May 2026